翰森制药：产品销售收入将快速增加，推广力度可能略加强-20260206

Investment Rating - The report maintains a "Buy" rating for the company with a target price adjusted to HKD 42.10 [4][7]. Core Insights - The company's product sales revenue is expected to continue growing rapidly, driven by the successful launch of key innovative drugs in the oncology and liver disease sectors [1][3]. - Increased promotional efforts are anticipated, particularly with the upcoming launch of the drug Amivantamab in the UK, which may lead to higher sales expenses [2]. - Long-term revenue from licensing agreements is expected to increase, particularly from a deal with Glenmark Specialty for the commercialization of Amivantamab in various regions [3]. Financial Summary - Revenue projections for the company are as follows: - 2023: RMB 10,104 million - 2024: RMB 12,261 million (21.3% growth) - 2025E: RMB 15,426 million (25.8% growth) - 2026E: RMB 15,600 million (1.1% growth) - 2027E: RMB 17,644 million (13.1% growth) [6][12] - Shareholder net profit estimates are: - 2023: RMB 3,278 million - 2024: RMB 4,372 million (33.4% growth) - 2025E: RMB 5,434 million (24.3% growth) - 2026E: RMB 4,739 million (-12.8% decline) - 2027E: RMB 5,828 million (23.0% growth) [6][12]. - The company’s earnings per share (EPS) are projected to be: - 2023: RMB 0.55 - 2024: RMB 0.74 - 2025E: RMB 0.92 - 2026E: RMB 0.79 - 2027E: RMB 0.98 [6][12]. Target Price and Valuation - The target price has been adjusted to HKD 42.10 based on a discounted cash flow (DCF) model, reflecting the company's growth potential despite an upward revision in sales expense forecasts [4][7].